B-type plexin antagonists and uses thereof

US9198966B2 · kind B2 · utility

Assignees

• RUPRECHT - KARLS - UNIVERSITÄT HEIDELBERG · DE
• Max-Planck-Gesellschaft zur Föderung der Wissenschaften e.V. · US

Inventors

• Stefan Offermanns · Bad Nauheim, DE
• Jakub Swiercz · Bad Nauheim, DE
• Thomas Worzfeld · Bad Nauheim, DE

Key dates

• Filing date: Feb 9, 2012
• Grant date: Dec 1, 2015
• Expiry date: Feb 9, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention concerns the field of cancer therapy. In particular, it relates to an antagonist of a B-type plexin which prevents the interaction of the B-type plexin with ErbB-2 for use as a medicament, in particular, for treating metastasizing cancer. The present invention also contemplates a method for identifying an antagonist which prevents the interaction of a B-type plexin with ErbB-2. Finally, the invention provides for a polynucleotide encoding a B-type plexin polypeptide which lacks a functional intracellular domain and the said polypeptide.